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Introduction: Recombinant factor VIIa (rFVIIa; NovoSeven) is well recognized as
an effective hemostatic agent in the management and prophylaxis of patients with
hemophilia. We report here the successful use of rFVIIa in a coagulopathic burn patient.
Methods: A 63-year-old man was admitted with signiﬁcant upper-body burns in a total
body surface area of 60%. Initial management included early intubation and escharo-
tomies,withsubsequentadmissiontotheburnunit.Fascialexcisionwascarriedoutwith
allograft placement. During a complicated hospital course, decline in platelet function
was noted and was associated with the development of a generalized coagulopathy with
elevated international normalized ratio. Following a routine follow-up debridement and
autografting, extensive bleeding was noted from donor sites. A period of increasing
hemodynamic instability followed in the burn unit, with serial hematocrit measurements
pointing toward ongoing bleeding from the surgical sites. Following administration of
signiﬁcant amounts of blood product, it was decided to administer rFVIIa per phar-
macy protocol. Results: Within 4 hours of administration of rFVIIa, the patient was
noted to be hemodynamically stable with unchanging serial hematocrit measurements.
Hemostasis was attributed to the use of rFVIIa with prior administration of platelets.
Conclusions: Our case demonstrates the successful use of rFVIIa in the severely coag-
ulopathic burn patient.
CASE REPORT
We present the case of a 63-year-old man who was admitted to our hospital with signiﬁcant
upper-body burns. The previous night he had been cooking when his clothing ignited. He
did not call for help until the following morning.
Initial assessment revealed approximately 60% total body surface area burn, most
of which was full thickness involving his torso and upper extremities. In addition, there
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was some minor involvement of his lower extremities. The patient complained of pain and
inability to pass urine. Limited history was obtained in the emergency department. The
patient denied any allergies and was not taking any medications.
Intubation for airway protection was performed early in the trauma room, and the pa-
tient was transferred to the burn unit where extensive fasciotomies to bilateral arms, hands,
chest, and abdomen were performed at the bedside. Initial laboratory reports revealed acute
renal failure with a creatinine level of 2.2, which marked the beginning of an undulating
course. The next day, the patient was taken to the operating room for his ﬁrst of several
procedures. Fascial excision of both arms and left ﬂank, with allograft, was performed.
Skin biopsy was taken per protocol, with a view to obtaining cultured epidermal autograft.
His hospital course was complicated by pneumonia and polymicrobial sepsis. Or-
ganisms isolated from blood and wound-bed cultures included Pseudomonas, Aspergillus,
vancomycin-resistant Enterococcus,a n dKlebsiella. Broad-spectrum antibiotic coverage
was instituted.
Bythesixthweekofhospitalization,adeclineinplateletfunctionwasnotedfrommore
than 150 × 109 to less than 15 × 109. This was paralleled by a generalized coagulopathy
with a rise in international normalized ratio to more than 1.52. At this time, the patient




Upon return to the burn unit, the patient became increasingly hemodynamically un-
stable, with serial hematocrit measurements revealing ongoing bleeding despite blood
transfusions. After 12 units of packed red blood cells, 16 units of fresh frozen plasma, and
16 units of platelets, consideration was given to recombinant activated factor VII (rFVIIa).
This was administered per pharmacy protocol, with subsequent stabilization of the patient
and cessation of ongoing blood losses. A dose of 90 μg/kg was chosen on the basis of the
use of the agent in other scenarios.
We present this case as a report of successful hemostasis in a patient with severe burn
injury after the administration of rFVIIa.
DISCUSSION
Recombinant factor VIIa (NovoSeven) was initially conceived and is well recognized as an
effective hemostatic agent in the management and prophylaxis of patients with hemophilia.
Almost identical to human factor VIIa, the recombinant form is genetically engineered
in cultured baby hamster kidney cells. An increasing body of evidence is appearing that
supports the use of rFVIIa in other situations that require prompt hemostasis.1
The traditionally understood coagulation cascade has come under scrutiny, and recent
work, most notably that of Hoffman et al,2−4 has given rise to the “cell-based” model of
coagulation. Three stages have been delineated:
1. Initiation: Endothelial injury exposes tissue factor (TF)-bearing cells. FVII binds to TF
and cleaves FX, which then binds to FVa on the TF-bearing cell surface. Thus, thrombin
is cleaved (by the FVa/Xa complex, thrombinase), which proceeds to cleave ﬁbrinogen
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in addition to activating platelets, stimulating the release of FVIII from von Willebrand
factor and activating FIXa. This stage is limited to the area of endothelial damage by
circulating tissue factor pathway inhibitors.
2. Ampliﬁcation: Occurring on the surface of activated platelets, the FVa/Xa complex
activates more thrombin, increasing ﬁbrin production and the formation of a ﬁbrin clot.
These platelets have been activated by the thrombin released in the initiation phase and
are characteristic in their expression of surface-binding sites for FVIIa/FXIa complex
(tenase) and thrombinase.
3. Propagation: The ﬁbrin clot increases in density as more platelets are activated in the
region of injury with the ampliﬁcation of this cascade. As mentioned, tissue factor
pathway inhibitor inhibits inappropriate initiation of clot outside the zone of injury.
Circulating antithrombin and protein C/S also play important roles in the limitation of
clot progression.
In the cell-based model of coagulation, FVIIa serves an important role both in the
initiation of coagulation and in the activation of platelets. The administration of higher
doses of rFVIIa has revealed that it can also function independently of TF by binding
directly to the surface of the activated platelet3 and activating FXa there with a burst of
ﬁbrin. Again, this coagulation activation is limited to the site of active bleeding both by
circulating inhibitors and by the requirement for activated platelets.
Our case demonstrates the use of rFVIIa as a hemostatic adjunct in a patient with
severe burn injury and life-threatening hemorrhage after surgery. His coagulopathy arose
from several factors including ongoing bleeding with the consumption of factors, systemic
sepsis, and uremia secondary to acute renal failure. Within hours of administration of
rFVIIa, the patient’s hemodynamic proﬁle improved, and serial hematocrit values revealed
that repeat transfusions were then no longer required.
It should be noted that prior to the administration of rFVIIa, platelet transfusion
was carried out. Case reports have demonstrated a reduction in bleeding time with rFVIIa
administrationinthesettingofthrombocytopenia4−7;thisbeingexplainedbythegeneration
of thrombin during the initiation phase by the TF/FVIIa complex. However, the efﬁcacy
is clearly greater in the presence of activated platelets, thereby invoking the ampliﬁcation
phase.
Of the off-label indications for rFVIIa, the use in septic patients or patients with burn
injury is regarded with some caution because of the risk of inadvertent overactivation of
the coagulation cascade with systemic coagulation. Nonetheless, there are case reports
of successful application of rFVIIa in critical situations, as illustrated by our patient.
Despite the sometimes inadequate efﬁcacy of the therapy in these situations, no thrombotic
complications have been observed.8
Itisimportanttocorrectallareasofthecoagulationcascadewhenfacedwithrefractory
bleeding. Balanced transfusion therapy9 should serve as the initial cornerstone of manage-
ment. Although the speciﬁc components of such an approach are variable, the transfusion
ofredbloodcellsshouldbeaccompaniedwithfreshfrozenplasmaandcryoprecipitate.10 In
uremic patients, or those at risk of platelet dysfunction, the adjunctive use of desmopressin
(DDAVP) should also be considered prior to the use of a novel agent such as rFVIIa.11,12
Recombinant factor VIIa, coupled with newfound understanding of the coagulation
cascade in vivo, has many promising applications in surgical therapy. There is increasing
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interest, in particular, in the use of this novel agent in the unique setting of patients
with burn injury in whom serial excisions and grafting are required, especially vulnerable
and compromised patients.13,14 Further case-controlled trials are necessary to conﬁrm the
efﬁcacy, safety, and ideal dosing of this novel drug in patients with burn injury.
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